HCPCS C9453: Injection, nivolumab, 1 mg

HCPCS Level II code C9453 denotes a per-milligram billing unit for nivolumab injection (1 mg) used in oncology and immunotherapy. This code is important nationally because nivolumab is a widely used immune checkpoint inhibitor with high-cost, weight- or dose-based administration that influences drug billing, site-of-care accounting, and payer coverage policies. Accurate coding at the per-milligram level affects claims adjudication, patient cost-sharing, and aggregate drug spend reporting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for nivolumab dosing, how the HCPCS Level II per-milligram code is applied in infusion and outpatient oncology settings, and what billing teams typically track when processing claims for high-cost biologics. The publication also summarizes national benchmarking elements such as unit-based pricing considerations, common payer coverage themes, and policy updates relevant to oncology infusions. Practical takeaways focus on coding clarity, site-of-service implications, and documentation alignment that influence reimbursement and reporting. Data not available in the input will be noted where applicable.

Billing Code Overview

HCPCS Level II code C9453 describes Injection, nivolumab, 1 mg. The service represented is the administration of the oncology monoclonal antibody nivolumab measured per milligram for the drug product. Typical site of service is infusion or outpatient oncology clinic where intravenous biologic therapies are prepared and delivered.

Data not available in the input.

Clinical Context

A typical patient is a 65-year-old with metastatic non–small cell lung cancer (NSCLC) presenting to an outpatient infusion center for systemic immunotherapy. The oncologist has prescribed nivolumab administered via IV infusion as part of a single-agent or combination immunotherapy regimen. Prior to the visit the patient undergoes eligibility verification, medication reconciliation, baseline labs (including CBC and CMP) and review of prior infusion tolerance. On the day of service the infusion nurse confirms identity, obtains vital signs, establishes peripheral IV or accesses an implanted venous port, and prepares the nivolumab dose per pharmacy using the billed unit C9453 which represents 1 mg increments of nivolumab. The nurse administers the infusion per protocol over the recommended infusion time while monitoring for infusion‑related reactions and immune‑related adverse events. Post‑infusion observation includes vital signs, documentation of tolerance, and scheduling of follow‑up oncology visits and subsequent infusion cycles. Typical sites of service are hospital outpatient infusion centers, physician office infusion suites, or standalone infusion centers that provide oncology biologic therapies.

Coding Specifications

Modifier	Description	When to Use
`24`	Unrelated Evaluation and Management service by the same physician during a postoperative period	Use when an unrelated E/M visit occurs on the same day as administration and global period applies

Taxonomy Code	Specialty	Notes
`207RG0100X`	Medical Oncology	Primary specialty prescribing and overseeing nivolumab infusions
`207RH0000X`	Hematology/Oncology	Providers who manage malignant hematologic and solid tumor immunotherapy
`363LF0000X`	Infusion Therapy	Nurses and facilities specializing in administration of IV biologic therapies
`261QM0800X`	Oncology Nurse Practitioner	Advanced practice clinicians managing oncology treatment and infusion follow-up
`207LP2900X`	Internal Medicine - Oncology	Hospitalists or internists with oncology focus involved in inpatient infusions

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Common indication for nivolumab in metastatic or recurrent non–small cell lung cancer
`C80.1`	Malignant (primary) neoplasm, unspecified site, metastatic disease	Used when metastatic disease site is unspecified and systemic immunotherapy is indicated
`C79.9`	Secondary malignant neoplasm of unspecified site	Denotes metastatic spread, often present when nivolumab is used
`C50.919`	Malignant neoplasm of unspecified site of right female breast	Breast cancer with advanced or refractory disease may be treated with checkpoint inhibitors in select cases
`C64.9`	Malignant neoplasm of unspecified kidney, except renal pelvis	Renal cell carcinoma is an established indication for nivolumab therapy

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used for billing the infusion administration time for the initial hour when nivolumab is infused in an outpatient or office setting
`96366`	Intravenous infusion; each additional hour (list separately in addition to code for primary procedure)	Used to report additional infusion time beyond the first hour when documentation supports extended infusion duration
`36415`	Collection of venous blood by venipuncture	Performed prior to infusion for baseline labs and monitoring; billed when venipuncture is done
`36561`	Insertion of tunneled centrally inserted central venous catheter, with subcutaneous port or pump, for long‑term infusion	Relevant when a port is placed to facilitate repeated nivolumab administrations
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used for certain non‑IV injections administered in same setting (less commonly used for nivolumab which is IV)
`36416`	Collection of capillary blood specimen	Used for point‑of‑care testing (e.g., fingerstick glucose) performed in infusion suite when clinically indicated

OpenPayer

Summary & Overview